GlassScriptPhysician profile
Richard Mattison
NPI 1821191040
$31,239.81
in general payments reported to CMS, 2019-2025
53 companies · $1,778 in 2025
The $1,778 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $68.94 · 2020: $592 · 2021: $1,938 · 2022: $1,131 · 2023: $979 · 2024: $25K · 2025: $1,778.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Food and Beverage: $6,215 · Travel and Lodging: $1,912 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,350.00 |
| Food and Beverage | $6,214.74 |
| Travel and Lodging | $1,912.18 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $23,696.16 | 2020-2025 | Zepbound, Mounjaro, Jardiance |
| Abbvie INC. | $1,533.65 | 2021-2025 | |
| Novo Nordisk INC | $1,345.83 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $645.19 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $360.91 | 2019-2025 | Jardiance, Ofev |
| Amgen INC. | $359.64 | 2021-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $233.20 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Astrazeneca Pharmaceuticals LP | $221.43 | 2020-2025 | Airsupra, Farxiga |
| Otsuka America Pharmaceutical, INC. | $208.11 | 2022-2025 | Rexulti |
| Lundbeck LLC | $199.87 | 2021-2025 | Rexulti, Vyepti |
| Takeda Pharmaceuticals U.S.A., INC. | $195.92 | 2020-2025 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $147.82 | 2021-2025 | |
| Amarin Pharma, INC. | $127.94 | 2020-2021 | |
| Janssen Scientific Affairs, LLC | $124.77 | 2020 | |
| Merck Sharp & Dohme LLC | $119.78 | 2020-2024 | Capvaxive, Gardasil 9, Gardasil |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $108.47 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $103.78 | 2022-2025 | Camzyos, Eliquis |
| Jazz Pharmaceuticals INC. | $102.32 | 2021 | |
| Viiv Healthcare Company | $100.34 | 2024-2025 | Cabenuva, Apretude |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $88.35 | 2023-2025 | Caplyta |
| Esperion Therapeutics, INC. | $69.56 | 2021-2025 | Nexletol |
| Kowa Pharmaceuticals America, INC. | $67.48 | 2021-2025 | Zoryve |
| Theratechnologies INC. | $66.57 | 2025 | Egrifta, Trogarzo |
| Eisai INC. | $65.06 | 2020 | |
| Medtronic, INC. | $63.80 | 2021-2025 | Intellis Adaptivestim |
| Boston Scientific Corporation | $58.22 | 2023-2025 | General - Male Sui |
| Novartis Pharmaceuticals Corporation | $57.29 | 2021-2023 | |
| Axsome Therapeutics, INC. | $54.79 | 2025 | Symbravo |
| Antares Pharma, INC. | $49.05 | 2021-2025 | Xyosted |
| Exact Sciences Corporation | $48.20 | 2023-2025 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $46.55 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $45.97 | 2022 | |
| Horizon Therapeutics Plc | $43.45 | 2021-2022 | |
| Astellas Pharma US INC | $41.66 | 2021-2025 | Veozah |
| Biohaven Pharmaceuticals, INC. | $37.40 | 2020-2021 | |
| Nevro Corp. | $36.12 | 2022-2023 | Senza |
| Arbor Pharmaceuticals, INC. | $35.51 | 2021 | |
| Azurity Pharmaceuticals, INC. | $34.54 | 2023-2024 | Edarbi, Edarbyclor |
| Janssen Pharmaceuticals, INC | $32.10 | 2022-2024 | Spravato |
| Dexcom, INC. | $29.91 | 2022-2023 | Dexcom G6 Transmitter |
| Vanda Pharmaceuticals INC. | $28.24 | 2025 | Hetlioz, Fanapt |
| Sanofi Pasteur INC. | $21.22 | 2020 | |
| Seqirus USA INC | $19.96 | 2021 | |
| Inogen, INC. | $19.73 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Philips North America LLC | $19.58 | 2024 | (Ck7) Extended Holter |
| Kyowa Kirin, INC. | $18.79 | 2024 | Crysvita |
| Irhythm Technologies, INC. | $16.68 | 2023 | Zio Xt Patch |
| Supernus Pharmaceuticals, INC. | $16.66 | 2022 | |
| Adlon Therapeutics L.P. | $15.14 | 2021 | |
| Dynavax Technologies Corporation | $14.90 | 2024 | Heplisav-B |
| Xeris Pharmaceuticals, INC. | $14.74 | 2021 | |
| Nabriva Therapeutics, Plc | $13.78 | 2021 | |
| Abbott Laboratories | $13.68 | 2025 | Eterna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Mattison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.